Neogen Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Neogen han disminuido a una tasa media anual de -80.6%, mientras que en la industria Medical Equipment los beneficios crecieron en un 13.6% anualmente. Los ingresos han ido creciendo a una tasa media de 14.7% al año.
Información clave
-80.62%
Tasa de crecimiento de los beneficios
-80.19%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.90% |
| Tasa de crecimiento de los ingresos | 14.71% |
| Rentabilidad financiera | -28.96% |
| Margen neto | -69.94% |
| Última actualización de beneficios | 28 Feb 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Apr 30
NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential
Analysts have nudged their price target on Neogen slightly higher to $12, reflecting updated assumptions around discount rate, profit margin and future P/E that keep fair value broadly in line with prior estimates. What's in the News Neogen updated full fiscal year 2026 guidance, with projected revenue now in a range of $857 million to $860 million.Actualización de narrativa • Apr 15
NEOG: Recall Response And Updated 2026 Guidance Will Support Future Upside
Analysts have raised their price target on Neogen from $11.67 to $12.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher future P/E of 32.21 compared with 28.61 previously. What's in the News Neogen updated full fiscal year 2026 guidance, indicating expected revenue in a range of $857 million to $860 million, compared with prior guidance of $845 million to $855 million (corporate guidance).Actualización de narrativa • Apr 01
NEOG: Earnings Outlook Will Benefit From Recall Actions And New Guidance
Analysts have raised their price target on Neogen from $8.17 to $11.67 per share, citing updated assumptions related to the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials.
Actualización de narrativa • Mar 18
NEOG: Recall Resolution Will Shape Bullish View On 2026 Revenue Outlook
Analysts have kept Neogen's price target steady at $13.00, indicating only minor adjustments in assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials, and is extending the recall to 2 mL / 20 mg vials while its investigation continues (Key Developments).Actualización de narrativa • Mar 04
NEOG: 2026 Outlook Will Rely On Recall Resolution For Upside
Analysts are holding Neogen's fair value estimate at $13.00 while modestly adjusting their assumptions around the discount rate, long term revenue trends, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the overall price target level.Actualización de narrativa • Feb 18
NEOG: 2026 Revenue Outlook Will Support Continued Bullish Thesis
Analysts have maintained Neogen's price target at $13.00, noting that only minor adjustments to assumptions around discount rate, revenue growth, profit margins, and future P/E were made, which do not materially change their valuation view. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level, after microbial contamination was identified in certain 10 mL/50 mg vials used via intraarticular injection, which is inconsistent with the product's labeled use (Key Developments).Seeking Alpha • Feb 16
Neogen Corporation Could Re-Rate As 3M Food Safety Integration Improves
Summary Neogen Corporation’s sizeable $11 billion food-and-animal safety TAM still has secular tailwinds with regulation, traceability, and disease-prevention trends. Management believes this market has an overall projected 6%–7% CAGR through 2030. In that context, NEOG’s Petrifilm anchors future recurring consumables and end-to-end testing ecosystem. NEOG’s 3M Food Safety combination expanded scale but introduced integration frictions, which, going forward, are an interesting opportunity for management. If NEOG executes on its turnaround plan with better supply chains, fulfillment, and systems, it could unlock long-term shareholder value. Read the full article on Seeking AlphaActualización de narrativa • Feb 03
NEOG: Higher Forward P/E And 2026 Outlook Will Support Bullish Thesis
Analysts have raised their price target on Neogen by an implied $3 per share, pointing to adjustments in fair value, discount rate, revenue growth expectations, profit margin assumptions, and a higher forward P/E multiple as the key drivers behind the change. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL/50 mg vials, with an expanded recall to 2 mL/20 mg vials while the investigation continues (Key Developments).Artículo de análisis • Feb 02
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Despite an already strong run, Neogen Corporation ( NASDAQ:NEOG ) shares have been powering on, with a gain of 46% in...
Actualización de narrativa • Jan 20
NEOG: Future CFO Transition And 2026 Guidance Will Support Measured Outlook
Analysts have raised their fair value estimate for Neogen from US$6.50 to US$10.00, reflecting updated assumptions regarding discount rates, revenue trends, profit margins and a higher future P/E multiple. What's in the News Neogen issued earnings guidance for fiscal 2026, with revenue anticipated in the range of US$845 million to US$855 million, giving investors a sense of management’s current expectations for the business (Key Developments).Actualización de narrativa • Jan 05
NEOG: New CFO Appointment Will Support Confidence In Earnings Outlook
Analysts now place a higher implied value on Neogen, lifting their fair value estimate from US$8.00 to US$10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a richer future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer, effective November 3, 2025.Artículo de análisis • Dec 19
Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth
The Neogen Corporation ( NASDAQ:NEOG ) share price has done very well over the last month, posting an excellent gain of...Actualización de narrativa • Dec 17
NEOG: Future CFO Transition And Guidance Stability Will Support Measured Outlook
Analysts have raised their price target on Neogen from approximately $5.00 to $6.50 per share, citing a slightly lower discount rate, modestly improved revenue trajectory, better profit margin expectations, and a willingness to assign a higher future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025, with outgoing CFO David Naemura supporting the transition through year end.Actualización de narrativa • Dec 03
NEOG: CFO Transition And Alliance Renewal Will Support Future Earnings
Analysts have modestly raised their price target on Neogen by about $0.20 per share, citing a slightly higher assumed discount rate and marginally richer future valuation multiples that together offset minor tweaks to long term growth and margin expectations. What's in the News Reaffirmed fiscal 2026 earnings guidance, maintaining full-year revenue expectations of $820 million to $840 million (company guidance).Actualización de narrativa • Nov 19
NEOG: Profit Margin Expansion And CFO Transition Will Drive Earnings Potential
Analysts have raised their price target for Neogen modestly, citing improved profit margin projections and a slightly lower expected future price-to-earnings ratio as key factors behind the adjustment. What's in the News Neogen appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025.Actualización de narrativa • Oct 31
NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion
Narrative Update: Neogen Analyst Price Target Revised Analysts have slightly raised their price target for Neogen, citing improvements in expected profit margins and a modest decline in projected future valuation multiples. This has resulted in a new estimated fair value of $8.17 per share.Actualización de narrativa • Oct 17
Food Safety Testing Advances Will Expand Global Opportunities
Neogen's analyst target price has risen from $7.67 to $8.17, as analysts point to improved revenue growth projections alongside a reduced discount rate, both supporting a higher valuation. What's in the News Neogen introduced Molecular Detection Assay: Listeria Right Now, a rapid, enrichment-free tool for detecting Listeria species with results in about two hours and streamlined workflow benefits (Product-Related Announcements).Actualización de narrativa • Oct 03
Food Safety Testing Advances Will Expand Global Opportunities
Analysts have raised their price target for Neogen from $6.50 to $7.67, citing a slightly lower discount rate and forward profit expectations. Revenue growth projections remain stable.Artículo de análisis • Jul 10
Is Neogen (NASDAQ:NEOG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Nueva narrativa • May 27
Food Safety And Genomics Will Expand Global Markets
Resilient core businesses, strategic divestitures, and efficiency initiatives are expected to stabilize revenue and expand margins as macro and operational conditions improve.Artículo de análisis • May 16
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 33% Jump Looks Justified
Those holding Neogen Corporation ( NASDAQ:NEOG ) shares would be relieved that the share price has rebounded 33% in the...Seeking Alpha • Apr 23
Neogen: A Fair Divestment (Rating Upgrade)
Summary Neogen's merger with 3M Food Safety led to significant debt and operational struggles, causing shares to plummet and the CEO to be ousted. Following disappointing sales and earnings, the company is exploring asset sales and restructuring, offering potential upside if stabilization occurs. Neogen's current valuation appears modest relative to sales, presenting a speculative opportunity for investors willing to take on risk. I am cautiously optimistic about Neogen's future, considering the potential for above-average returns if divestments are executed at reasonable valuations. Read the full article on Seeking AlphaArtículo de análisis • Apr 11
Here's Why Neogen (NASDAQ:NEOG) Is Weighed Down By Its Debt Load
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 14
Neogen: Food Safety Play Is Far From A Safe Pay
Summary Neogen Corporation's merger with 3M Food Safety in 2022 led to significant challenges, including valuation compression, debt increase, and underperformance, causing shares to plummet. Neogen's financial performance has been disappointing, with sales and EBITDA falling short of expectations and net debt increasing. The company's guidance for 2025 remains modest, and recent results have shown minimal revenue growth and high leverage ratios, frustrating investors. Trading at $12, NEOG's future hinges on management's ability to execute and deliver on promised EBITDA improvements to reduce leverage and boost earnings. Read the full article on Seeking AlphaArtículo de análisis • Dec 03
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
It's not a stretch to say that Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 3.3x right now...Artículo de análisis • Nov 07
Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Oct 11
Neogen Stock: Expect Volatility To Continue Amid Weak Growth
Summary Neogen reported its Q1 earnings, which missed expectations. Weak demand trends across food and animal safety end markets have pressured the sales outlook. We expect shares to remain volatile until there is evidence of a growth rebound. Read the full article on Seeking AlphaArtículo de análisis • Aug 28
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 4x may not look like an appealing investment...Artículo de análisis • Jul 31
We Think Neogen (NASDAQ:NEOG) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Jun 26
Neogen Corporation: Challenges Remain
Summary Today, we look at Neogen Corporation, which operates in the food and animal safety segments, offering diagnostic test kits, and other related products. The company is currently still integrating the food safety operations of 3M, Neogen's latest acquisition. That integration is proceeding apace, and there was some insider buying in the shares in April following quarterly results. An analysis around Neogen follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • May 21
There's Reason For Concern Over Neogen Corporation's (NASDAQ:NEOG) Price
It's not a stretch to say that Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 3.2x right now...Seeking Alpha • Apr 15
Battered By M&A Integration Issues, Neogen Has To Rebuild Investor Trust
Summary Neogen's acquisition of 3M's food safety operations has done far more harm than good in the short term, as integration issues have undermined financial performance and credibility with investors. The company's disappointing FQ3'24 results and ongoing operating inefficiencies have led to another cut in guidance for revenue and EBITDA, and the shares are near a 52-week low. These integration challenges won't go on forever, and Neogen will emerge as a larger, stronger player in the global food safety market. I believe Neogen's shares should trade in the mid-teens, with further upside tied to a reversal of these disappointing revenue and margin trends, but rebuilding investor trust is key. Read the full article on Seeking AlphaDesglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Neogen. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 28 Feb 26 | 871 | -609 | 410 | 20 |
| 30 Nov 25 | 880 | -603 | 412 | 20 |
| 31 Aug 25 | 887 | -1,043 | 408 | 21 |
| 31 May 25 | 895 | -1,092 | 400 | 21 |
| 28 Feb 25 | 906 | -485 | 397 | 20 |
| 30 Nov 24 | 914 | -476 | 397 | 20 |
| 31 Aug 24 | 912 | -24 | 389 | 21 |
| 31 May 24 | 924 | -9 | 383 | 22 |
| 29 Feb 24 | 929 | 2 | 318 | 24 |
| 30 Nov 23 | 919 | 12 | 356 | 27 |
| 31 Aug 23 | 919 | -27 | 334 | 28 |
| 31 May 23 | 822 | -23 | 342 | 26 |
| 28 Feb 23 | 721 | -13 | 267 | 23 |
| 30 Nov 22 | 631 | -16 | 185 | 20 |
| 31 Aug 22 | 531 | 36 | 145 | 18 |
| 31 May 22 | 527 | 48 | 142 | 17 |
| 28 Feb 22 | 514 | 49 | 154 | 17 |
| 30 Nov 21 | 503 | 57 | 133 | 17 |
| 31 Aug 21 | 487 | 62 | 128 | 17 |
| 31 May 21 | 468 | 61 | 122 | 16 |
| 28 Feb 21 | 450 | 61 | 120 | 16 |
| 30 Nov 20 | 433 | 60 | 114 | 15 |
| 31 Aug 20 | 426 | 61 | 113 | 15 |
| 31 May 20 | 418 | 59 | 114 | 15 |
| 29 Feb 20 | 419 | 59 | 114 | 15 |
| 30 Nov 19 | 417 | 60 | 112 | 14 |
| 31 Aug 19 | 416 | 60 | 112 | 14 |
| 31 May 19 | 414 | 60 | 111 | 13 |
| 28 Feb 19 | 413 | 62 | 109 | 11 |
| 30 Nov 18 | 410 | 65 | 109 | 11 |
| 31 Aug 18 | 403 | 66 | 107 | 11 |
| 31 May 18 | 398 | 63 | 105 | 11 |
| 28 Feb 18 | 389 | 58 | 104 | 11 |
| 30 Nov 17 | 382 | 52 | 102 | 11 |
| 31 Aug 17 | 372 | 46 | 99 | 11 |
| 31 May 17 | 358 | 44 | 94 | 10 |
| 28 Feb 17 | 353 | 41 | 95 | 10 |
| 30 Nov 16 | 341 | 39 | 93 | 10 |
| 31 Aug 16 | 330 | 37 | 90 | 10 |
| 31 May 16 | 321 | 37 | 87 | 10 |
| 29 Feb 16 | 310 | 36 | 84 | 10 |
| 30 Nov 15 | 301 | 35 | 81 | 10 |
| 31 Aug 15 | 290 | 34 | 79 | 10 |
| 31 May 15 | 283 | 34 | 77 | 10 |
Ingresos de calidad: NEOG actualmente no es rentable.
Margen de beneficios creciente: NEOG actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: NEOG no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 80.6% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de NEOG en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: NEOG no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (14.8%).
Rentabilidad financiera
Alta ROE: NEOG tiene una rentabilidad financiera negativa (-28.96%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 19:10 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/02/28 |
| Ingresos anuales | 2025/05/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Neogen Corporation está cubierta por 16 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Robert Labick | CJS Securities, Inc. |
| David Westenberg | CL King & Associates, Inc. |